Hemab Therapeutics Statistics
NASDAQ: COAGHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
39.29-0.57 (-1.43%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Hemab Therapeutics by the numbers
Hemab Therapeutics has a market capitalization of $1.84 billion based on 46.73M shares outstanding. With trailing EPS of $-3.55, Hemab Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 7.0% above its 50-day average and 5.4% above its 200-day average.
Average daily trading volume is 495.96K shares, or about $19.5 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
COAG valuation vs. peer median
| Metric | COAG | Peer median | Difference |
|---|---|---|---|
| Market cap | $1.84B | $1.72B | +7% |
| Avg. volume | 495.96K | 2.25M | -78% |
Peer median across 8 companies: BCRX, REPL, LYCA, MAZE, VIR, BEAM, RXRX, ALVO.
Valuation
- Market cap
- $1.84B
- EPS (TTM)
- $-3.55
- Shares outstanding
- 46.73M
Price and trading
- Previous close
- 39.86
- Open
- 39.50
- Day range
- 38.77 – 40.19
- 52-week range
- 23.00 – 55.42
- Beta
- —
- Volume
- 347.01K
- Average volume
- 495.96K
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 10, 2026
Additional statistics
- Market Cap
- 1.84B
- Forward Pe
- -14.82
- Eps
- -3.55
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 55.42
- Week52 Low
- 23.00
- Avg Volume
- 495.96K
- Shares Outstanding
- 46.73M
- Ma50
- 36.72
- Ma200
- 37.27
- Earnings Date
- Nov 10, 2026
- Pct From52w High
- -29.11%
- Pct From52w Low
- 70.83%